case study寫(xiě)作-aurobindo制藥公司案例研究

1、wangke.專(zhuān)業(yè)留學(xué)生網(wǎng)課代修輔導(dǎo)中心wangke.為留學(xué)生提供高效、優(yōu)質(zhì)的網(wǎng)課代修服務(wù)casestudy寫(xiě)作Aurobindo制藥公司案例研究AOnAurobindoPharmaGlobalstrategyfIndianpharmacycompaniestheopptunityinemergingmarkets:AcasestudyonAurobindoPharmaFocusAim:TounderstthetrendsinIndia

2、npharmacycompanieswhichhavebeenrecentlygoingglobalbyinvestingabroadwithanintentionfmarketexpansion網(wǎng)課代修wangke.Objectives:TofindoutthestrengthsoftheIndianPharmaceuticalIndustryanalysethepatternofMergersAcquisitionsbyvariou

3、scompaniesacrosstheglobe.TothrowlightonthestrategiesfollowedbyAurobindoPharmainacquiringotherpharmacompanies.ContextTheresearchincludesstrategyoftheemergingpharmaceuticalcompaniesinIndiaunderststhetrendsprocessofthecompa

4、niesthathavebeengoingglobaltoexptheirmarketinthewldwide.Literaturereview:InpharmaceuticalsectaroundthewldIndiaranks4thintermsofvolume13thintermsofvalue.Intheyear2006thevaluewasUSD7.42billionthegrowthhasbeenincreasedby12.

5、9%overthepreviousyear.Inthistotalsales90%ofthesalesareaccountedasgenericstheremainingarepatenteddrugs.Nowaday’sgovernmentsofvariouscountriespatientsindustriesarepullingattentiontowardsgenericdrugsduetolowerincostlessRWoc

6、khardtLupinNicholasPiramalaredoingwellindevelopedmarketsuchasUSEurope.Thesecompanieshaveexcitingvaluesinfmulationbulkdrugsgenericsnoveldrugdeliverysystemnewchemicalentitiesbiotechnologyetc(ResearchMarkets2007).wangke.專(zhuān)業(yè)留

7、學(xué)生網(wǎng)課代修輔導(dǎo)中心wangke.為留學(xué)生提供高效、優(yōu)質(zhì)的網(wǎng)課代修服務(wù)MainlyUSEuropeancountrieshavefocusedonIndianduetothevastchangeinresearchwkdonethemainpluspointsfthemwerethelawsofIndiangovernmenthavechangeddrasticallylikeprovidingnewopptunitiestolaunc

8、hpatentedmoleculesthispointmadetheminterestininvestingIndianpharmaceuticalslikewiseIndiapharmaisbecomingstrongmanufacturingstwithlowcostdevelopmentmanufacturingdestination.Source:ShivaniShukla2006.Theglobalhasbeenrapidly

9、changingintothegenericmarketherearesomecompaniesthathavebeeninvestedacquireddealsin200809.GreencrossPharmainSingapewasacquiredbyentPfizerplantinIrelwasacquiredbyHovionePharmaPromanufacturingfacilitywasacquiredbyURLPharma

10、ECRpharmaceuticalswasacquiredbyHITechpharmacal.Source:ResearchMarkets2009.IndianpharmaceuticalmarketinU.S.hasbeencontinuouslyincreasinga$440billionmarketappoints47%oftheglobalpharmaceuticalmarket.InFebruary2009Indianphar

11、maceuticalcompaniesincludinglargesizedalltogetherhaveassuredapprovalsf15AbbreviatedNewDrugApplications(As)(Indusview2009).Strategies:Indertoexptheirmarketsomecompanieshaveenteredintofeignmarketsingenericdrugssegment.Some

12、companieshaveentereddirectlybysettingtheirownsalesmarketingganisationeitheringanicmannerthroughacquisitionsothershaveenteredthesemarketthroughpartnershipmergingwithwellestablishedcompanies.RanbaxyacquiredOhmLabatiesinUSi

13、n1995JubilantganosysacquiredCadistapharmaceuticals(fmerlyTrigenLabaties)anUSgenericcompanyin2005.AurobindoPharmagainedanFDAcomplimentfmulationsmanufacturingplantinDaytonNewJerseyin2006inthesameyearthecompanyacquiredMilph

14、armLTDinUK.Dr.Reddy’sapprovedasaMHRAmanufacturingfacilitiesinUK.WockhardthasamanufacturingfacilityinUKIrelFrance(espicom2009).AurobindoPharma:Aurobindowasfoundedintheyear1986byMrP.V.RamaprasadreddyMr.K.Nithyanareddysomeh

15、ighlycommittedgroupprofessionals.AurobindopharmalaunchesAsia’slargestfmulationfacilityinIndiain2009.Visionofthecompanyis“TobecomeAsiasleadingoneamongthetop15genericPharmacompaniesinthewldby2015“(aurobindo2009).R&Doftheco

16、mpanyliesindevelopingintellectualpropertyinnoninfringingprocessesresolvingcomplexchemistrychallenges.Aurobindopharmaexpectstoreach$2billionbytheendoftheyear2013thecompanylicensingdealwithPfizertosellgenericsdrugsinmethan